Despite curative intent, prostate cancer recurs in a substantial proportion of patients after initial treatment. After external beam radiation therapy (EBRT), approximately 30-50% of patients experience disease recurrence within 10 years. After radical prostatectomy, recurrence rates of 15-40% are reported at 10 years depending on pathological features. When cancer returns locally, a second curative treatment -- called salvage therapy -- may be possible.
Salvage cryotherapy is a technique that destroys recurrent prostate cancer by freezing tissue to lethal temperatures. It is performed percutaneously (through the skin) using probes inserted through the perineum under transrectal ultrasound (TRUS) guidance. The procedure uses two freeze-thaw cycles to ensure complete cell death, while a urethral warming catheter protects the urethra from freeze injury.
The appeal of cryotherapy in the salvage setting is that it avoids the major surgical risks of salvage radical prostatectomy -- the most oncologically effective but technically demanding option -- while still targeting the prostate directly. Compared to re-irradiation, cryotherapy does not add further radiation dose to surrounding tissues that may already have been exposed during primary treatment.
This review synthesizes evidence on both whole-gland and focal salvage cryotherapy, covering patient selection, imaging-guided recurrence detection, oncologic outcomes, complication rates, and comparisons with other salvage modalities including high-intensity focused ultrasound (HIFU) and salvage radical prostatectomy.
Accurate localization of recurrent disease is a prerequisite for salvage treatment. PSMA PET-CT (prostate-specific membrane antigen positron emission tomography) has revolutionized recurrence detection by identifying sites of disease at PSA levels where conventional imaging was blind. Detection rates increase with PSA level: approximately 36.2% at PSA below 0.5 ng/mL, rising to 96.7% when PSA is 5 ng/mL or higher.
Multiparametric MRI (mpMRI) provides high-resolution anatomical detail and functional information through sequences including diffusion-weighted imaging (DWI) and T2-weighted imaging. Combining DWI and T2W imaging improves sensitivity for local recurrence to approximately 62%, compared to only 25% for T2W imaging alone. mpMRI is particularly valuable for mapping the location of recurrent tumor within the gland to guide focal treatment planning.
For patients being considered for focal salvage cryotherapy, mpMRI and PSMA PET work in combination: PSMA PET confirms that disease is localized to the prostate rather than metastatic, while mpMRI precisely maps the intraprostatic target. Biopsy remains important to confirm histologic recurrence and obtain updated Gleason grading before committing to salvage therapy.
The strongest predictors of favorable outcomes after salvage cryotherapy are factors reflecting the burden and aggressiveness of recurrent disease. A pre-salvage PSA below 5-10 ng/mL is consistently associated with better biochemical recurrence-free survival across studies. Rising PSA at the time of salvage reflects more advanced disease that is harder to eradicate completely.
Gleason score at recurrence biopsy is another key predictor. Patients with Gleason score 7 or lower at the time of salvage have substantially better outcomes than those with Gleason 8-10 recurrences. High-grade recurrences are biologically more aggressive and may not be fully sterilized by cryotherapy alone.
Clinical staging also matters: patients with T1-T2 disease at recurrence (cancer confined to or just at the edge of the prostate) fare better than those with T3-T4 disease (extension beyond the capsule or into adjacent structures). PSMA PET or CT staging is used to exclude lymph node or distant metastases, as salvage local therapy has limited benefit when disease has spread beyond the pelvis.
Whole-gland salvage cryotherapy freezes the entire prostate and is used when recurrence is multifocal or when the location cannot be reliably mapped to a focal area. Across published series, biochemical recurrence-free survival (BRFS) at 5 years ranges from approximately 43% to 67%, with variation explained largely by patient selection -- studies with lower pre-salvage PSA thresholds report better outcomes.
Urinary complications are the most common side effects. Urinary incontinence rates of approximately 16% are reported with modern techniques, lower than in older series where urethral protection was less refined. Erectile dysfunction occurs in 14-86% of patients depending on baseline function and whether nerve-sparing attempts are made -- the wide range reflects differences in patient age, prior treatment, and how erectile function is assessed.
Other reported complications include urethrorectal fistula (abnormal connection between the urethra and rectum), occurring in approximately 1-3% of cases, and urethral sloughing -- shedding of dead urethral tissue -- which can cause obstructive urinary symptoms. Rectal injury, while rare with modern TRUS guidance, remains a feared complication given the proximity of the rectum to the posterior prostate surface.
Focal salvage cryotherapy targets only the region of the prostate where recurrence is mapped, preserving the neurovascular bundles and healthy tissue elsewhere. The rationale is that if recurrence is truly unifocal and well-localized on imaging, treating only the affected area can achieve comparable oncologic control while substantially reducing side effects.
Biochemical recurrence-free survival for focal salvage cryotherapy at 5 years ranges from approximately 46% to 73% in published series, with better outcomes in low-risk patients (lower PSA and Gleason score at recurrence). These figures are broadly comparable to whole-gland cryotherapy outcomes in similar patient populations, supporting the oncologic equivalence of focal treatment when patients are properly selected.
The key advantage of focal treatment is the substantially lower complication profile. Rates of de novo urinary incontinence are significantly lower than with whole-gland treatment. Preservation of erectile function is more likely with focal cryotherapy since the neurovascular bundles on the contralateral side are spared. These quality-of-life advantages make focal treatment appealing for patients who highly value functional outcomes.
Salvage radical prostatectomy (SRP) is technically demanding in the post-radiation setting due to tissue fibrosis and altered anatomy, but offers the advantage of complete pathologic staging and potentially superior long-term cancer control. Reported BRFS rates for SRP are generally higher than for cryotherapy at 10 years, but complication rates -- including incontinence and anastomotic stricture -- are also substantially higher. Cryotherapy is preferred when the operative risk of SRP is considered unacceptable.
High-intensity focused ultrasound (HIFU) is an alternative non-surgical salvage modality that uses focused ultrasound energy to thermally ablate prostate tissue. It offers comparable morbidity to cryotherapy in many series. However, HIFU relies on a clear acoustic pathway, and prior brachytherapy (radioactive seed implantation) can create acoustic shadowing from the seeds that interferes with ultrasound energy delivery. Cryotherapy is therefore generally preferred over HIFU in patients who received brachytherapy as their primary treatment.
Emerging options including stereotactic body radiation therapy (SBRT) and salvage brachytherapy boost are also being explored for local recurrence after radiation. These techniques may be appropriate for selected patients but involve further radiation to already-treated tissue and carry their own toxicity profiles. The optimal choice among salvage modalities depends on the individual patient's prior treatment, functional status, tumor characteristics, and values.
The review concludes that both whole-gland and focal salvage cryotherapy are reasonable options for carefully selected patients with locally recurrent prostate cancer, particularly for those who are not candidates for or decline salvage surgery. The evidence base consists primarily of retrospective single-institution series with heterogeneous patient populations, limiting the strength of conclusions that can be drawn.
The lack of prospective randomized trials comparing cryotherapy to other salvage modalities remains a significant gap. Without head-to-head comparisons using standardized patient selection criteria and outcome reporting, it is difficult to recommend one salvage approach definitively over another. Most guidelines describe cryotherapy as an acceptable option rather than a preferred standard of care.
Future directions include better integration of PSMA PET-guided treatment planning to refine patient selection, development of standardized reporting criteria for salvage oncologic outcomes, and prospective multi-institutional studies powered to detect clinically meaningful differences in BRFS and quality of life between salvage approaches. As focal therapies mature and imaging resolution improves, the shift toward targeted rather than whole-gland ablation is expected to continue.